Top

Child's Nervous System

Published in:

01-10-2020 | Spinal Tumor | Annual issue paper

Spinal manifestations of Neurofibromatosis type 1

Authors: Ben Shofty, Ori Barzilai, Morsi Khashan, Zvi Lidar, Shlomi Constantini

Published in: Child's Nervous System | Issue 10/2020

Abstract

Background

Neurofibromatosis type 1 (NF1) patients may present a wide spectrum of spinal pathologies. Osseous changes may lead to severe deformities with significant implications on growth and quality of life. Neurogenic tumors and soft tissue abnormalities may cause neuropathic pain and dysfunction ranging from minor paresthesias to profound motor and sensory deficits. Advanced imaging such as whole-body MRI, and volumetric tumor burden assessment have an evolving role in the evaluation and follow-up of patients with high spinal tumor load. Novel biological agents that target the hyperactivated ras pathway are currently under investigation and are reshaping current and future treatment paradigms. Surgical interventions for benign and malignant tumors, as well as deformity correction remain pivotal in treatment frameworks and require careful assessment by a dedicated multidisciplinary team.

Purpose

In this manuscript we review the various spinal manifestations of NF1 patients, indication for surgical intervention and oncological treatments.

Restrepo CS, Riascos RF, Hatta AA, Rojas R (2005) Neurofibromatosis type 1: spinal manifestations of a systemic disease. J Comput Assist Tomogr 29:532–539CrossRef

NIH (1988) NIH consensus development conference. Neurofibromatosis Conference statement. Arch Neurl:575–578

Patel NB, Stacy GS (2012) Musculoskeletal manifestations of neurofibromatosis type 1. AJR Am J Roentgenol 199:W99–W106. https://doi.org/10.2214/AJR.11.7811CrossRefPubMed

Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T, Pöyhönen M, Peltonen J, Peltonen S (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904–906. https://doi.org/10.1038/jid.2014.465CrossRefPubMed

Thakkar SD, Feigen U, Mautner VF (1999) Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety. Neuroradiology 41:625–629CrossRef

Taleb FS, Guha A, Arnold PM, Fehlings MG, Massicotte EM (2011) Surgical management of cervical spine manifestations of neurofibromatosis type 1: long-term clinical and radiological follow-up in 22 cases. J Neurosurg Spine 14:356–366. https://doi.org/10.3171/2010.9.SPINE09242CrossRefPubMed

Goertz O, Langer S, Uthoff D, Ring A, Stricker I, Tannapfel A, Steinau HU (2014) Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors. Anticancer Res 34:777–783PubMed

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ (2015) Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis clinical trials consortium phase II study. Neuro-oncology 17:596–603. https://doi.org/10.1093/neuonc/nou235CrossRefPubMed

Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, Pollack IF, Goodwin A, Manley PE, Fangusaro J, Allen R, Widemann BC (2017) Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-oncology 19:289–297. https://doi.org/10.1093/neuonc/now158CrossRefPubMed

10.

Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DA, Clapp DW, Chen S (2016) Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr Blood Cancer 63:206–213. https://doi.org/10.1002/pbc.25763CrossRefPubMed

11.

Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim AR, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375:2550–2560. https://doi.org/10.1056/NEJMoa1605943CrossRefPubMedPubMedCentral

12.

Ruggieri M, Polizzi A, Spalice A, Salpietro V, Caltabiano R, D'Orazi V, Pavone P, Pirrone C, Magro G, Platania N, Cavallaro S, Muglia M, Nicita F (2015) The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features. Clin Genet 87:401–410. https://doi.org/10.1111/cge.12498CrossRefPubMed

13.

Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF (2014) Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neuro-Oncol 116:307–313. https://doi.org/10.1007/s11060-013-1293-1CrossRef

14.

Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR (2014) Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 164A:1431–1437. https://doi.org/10.1002/ajmg.a.36466CrossRefPubMed

15.

Mautner V-F, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM (2008) Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-oncology 10:593–598. https://doi.org/10.1215/15228517-2008-011CrossRefPubMedPubMedCentral

16.

Pratt L, Helfer D, Weizman L, Shofty B, Constantini S, Joskowicz L, Ben Bashat D, Ben-Sira L (2015) Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice. Acta Neurochir 157:855–861. https://doi.org/10.1007/s00701-015-2366-zCrossRefPubMed

17.

Well L, Salamon J, Kaul MG, Farschtschi S, Herrmann J, Geier KI, Hagel C, Bockhorn M, Bannas P, Adam G, Mautner VF, Derlin T (2019) Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro-oncology 21:508–516. https://doi.org/10.1093/neuonc/noy199CrossRefPubMed

18.

Reinert CP, Schuhmann MU, Bender B, Gugel I, la Fougère C, Schäfer J, Gatidis S (2019) Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging 46:776–787. https://doi.org/10.1007/s00259-018-4227-5CrossRefPubMed

19.

Khong P-L, Goh WHS, Wong VCN, Fung CW, Ooi GC (2003) MR imaging of spinal tumors in children with neurofibromatosis 1. AJR Am J Roentgenol 180:413–417. https://doi.org/10.2214/ajr.180.2.1800413CrossRefPubMed

20.

Ramachandran M, Tsirikos AI, Lee J, Saifuddin A (2004) Whole-spine magnetic resonance imaging in patients with neurofibromatosis type 1 and spinal deformity. J Spinal Disord Tech 17:483–491. https://doi.org/10.1097/01.bsd.0000133466.97241.50CrossRefPubMed

21.

Durrani AA, Crawford AH, Chouhdry SN, Saifuddin A, Morley TR (2000) Modulation of spinal deformities in patients with neurofibromatosis type 1. Spine 25:69–75. https://doi.org/10.1097/00007632-200001010-00013CrossRefPubMed

22.

Kim HW, Weinstein SL (1997) Spine update. The management of scoliosis in neurofibromatosis. Spine 22:2770–2776. https://doi.org/10.1097/00007632-199712010-00014CrossRefPubMed

23.

Betz RR, Iorio R, Lombardi AV et al (1989) Scoliosis surgery in neurofibromatosis. Clin Orthop Relat Res:53–56

24.

Crawford AH (1989) Pitfalls of spinal deformities associated with neurofibromatosis in children. Clin Orthop Relat Res:29–42

25.

Sirois JL, Drennan JC (1990) Dystrophic spinal deformity in neurofibromatosis. J Pediatr Orthop 10:522–526CrossRef

26.

Tauchi R, Kawakami N, Castro MA, Ohara T, Saito T, Morishita K, Yamauchi I (2020) Long-term surgical outcomes after early definitive spinal fusion for early-onset scoliosis with neurofibromatosis type 1 at mean follow-up of 14 years. J Pediatr Orthop 40:42–47. https://doi.org/10.1097/BPO.0000000000001090CrossRefPubMed

27.

Tsirikos AI, Saifuddin A, Noordeen MH (2005) Spinal deformity in neurofibromatosis type-1: diagnosis and treatment. Eur Spine J 14:427–439. https://doi.org/10.1007/s00586-004-0829-7CrossRefPubMedPubMedCentral

28.

Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44:81–88. https://doi.org/10.1136/jmg.2006.045906CrossRefPubMed

29.

Mauda-Havakuk M, Shofty B, Ben-Shachar S, Ben-Sira L, Constantini S, Bokstein F (2017) Spinal and paraspinal plexiform neurofibromas in patients with neurofibromatosis type 1: a novel scoring system for radiological-clinical correlation. Am J Neuroradiol 38:1869–1875. https://doi.org/10.3174/ajnr.A5338CrossRefPubMed

30.

McLaughlin ME, Jacks T (2003) Progesterone receptor expression in neurofibromas. Cancer Res 63:752–755PubMed

31.

Well L, Jaeger A, Kehrer-Sawatzki H, Farschtschi S, Avanesov M, Sauer M, de Sousa MT, Bannas P, Derlin T, Adam G, Mautner VF, Salamon JM (2020) The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1. PLoS One 15:e0232031. https://doi.org/10.1371/journal.pone.0232031CrossRefPubMedPubMedCentral

32.

Shofty B, Mauda-Havakuk M, Ben-Sira L, Bokstein F, Lidar Z, Salame K, Korn A, Constantini S (2020) Surgical management of “kissing” spinal plexiform neurofibromas in neurofibromatosis type 1 patients. World Neurosurg 134:e1143–e1147. https://doi.org/10.1016/j.wneu.2019.11.124CrossRefPubMed

33.

Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, Korf BR, Babovic-Vuksanovic D, Packer RJ, Belasco J, Goldman S, Jakacki R, Kieran M, Steinberg SM, Widemann BC (2007) NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68:643–647. https://doi.org/10.1212/01.wnl.0000250332.89420.e6CrossRefPubMed

34.

Evans DGR, Birch JM, Ramsden RT et al (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289–294. https://doi.org/10.1136/jmg.2005.036319CrossRefPubMed

35.

Marjanska A, Galazka P, Wysocki M, Styczynski J (2020) New frontiers in therapy of peripheral nerve sheath tumors in patients with neurofibromatosis type 1: latest evidence and clinical implications. Anticancer Res 40:1817–1831. https://doi.org/10.21873/anticanres.14136CrossRefPubMed

36.

Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A (2017) Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1–10. https://doi.org/10.1016/j.humpath.2017.05.010CrossRefPubMedPubMedCentral

37.

Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE (2018) The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro-oncology 20:818–825. https://doi.org/10.1093/neuonc/noy013CrossRefPubMedPubMedCentral

38.

Akshintala S, Baldwin A, Liewehr DJ, Goodwin A, Blakeley JO, Gross AM, Steinberg SM, Dombi E, Widemann BC (2020) Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro-oncology. https://doi.org/10.1093/neuonc/noaa053

39.

Nelson CN, Dombi E, Rosenblum JS, Miettinen MM, Lehky TJ, Whitcomb PO, Hayes C, Scott G, Benzo S, Widemann BC, Chittiboina P (2019) Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg:1–11. https://doi.org/10.3171/2019.7.JNS191353

40.

Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006–2021CrossRef

41.

Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62:1573–1577PubMed

42.

Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311–314CrossRef

43.

Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z (2013) Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg 118:142–148. https://doi.org/10.3171/2012.9.JNS101610CrossRefPubMed

44.

Chou D, Bilsky MH, Luzzati A, Fisher CG, Gokaslan ZL, Rhines LD, Dekutoski MB, Fehlings MG, Ghag R, Varga P, Boriani S, Germscheid NM, Reynolds JJ, _ _ (2017) Malignant peripheral nerve sheath tumors of the spine: results of surgical management from a multicenter study. J Neurosurg Spine 26:291–298. https://doi.org/10.3171/2016.8.SPINE151548CrossRefPubMed

45.

Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA (2018) Malignant peripheral nerve sheath tumors: a single institution’s experience using combined surgery and radiation therapy. Am J Clin Oncol 41:465–470. https://doi.org/10.1097/COC.0000000000000303CrossRefPubMedPubMedCentral

46.

Akhavan A, Binesh F, Ghannadi F, Navabii H (2012) Excellent response of malignant peripheral nerve sheath tumour of retroperitoneum to radiation therapy. BMJ Case Rep 2012:bcr2012007266. https://doi.org/10.1136/bcr-2012-007266CrossRefPubMedPubMedCentral

47.

Shin D-W, Sohn M-J, Kim H-S, Lee DJ, Jeon SR, Hwang YJ, Jho EH (2015) Clinical analysis of spinal stereotactic radiosurgery in the treatment of neurogenic tumors. J Neurosurg Spine 23:429–437. https://doi.org/10.3171/2015.1.SPINE14910CrossRefPubMed

48.

Constantini S, Houten J, Miller DC, Freed D, Ozek MM, Rorke LB, Allen JC, Epstein FJ (1996) Intramedullary spinal cord tumors in children under the age of 3 years. J Neurosurg 85:1036–1043. https://doi.org/10.3171/jns.1996.85.6.1036CrossRefPubMed

49.

Constantini S, Miller DC, Allen JC, Rorke LB, Freed D, Epstein FJ (2000) Radical excision of intramedullary spinal cord tumors: surgical morbidity and long-term follow-up evaluation in 164 children and young adults. J Neurosurg 93:183–193. https://doi.org/10.3171/spi.2000.93.2.0183CrossRefPubMed

50.

Yagi T, Ohata K, Haque M, Hakuba A (1997) Intramedullary spinal cord tumour associated with neurofibromatosis type 1. Acta Neurochir 139:1055–1060. https://doi.org/10.1007/BF01411560CrossRefPubMed

51.

Uchi T, Inaoka T, Kitamura N, Ishikawa R, Nakatsuka T, Kasuya S, Tokuyama W, Hiruta N, Takahashi H, Terada H (2020) Unexpected discovery of a diffuse astrocytoma of the conus medullaris in an elderly NF1 patient. Radiol Case Rep 15:784–788. https://doi.org/10.1016/j.radcr.2020.02.033CrossRefPubMedPubMedCentral

52.

Lee M, Rezai AR, Freed D, Epstein FJ (1996) Intramedullary spinal cord tumors in neurofibromatosis. Neurosurgery 38:32–37. https://doi.org/10.1097/00006123-199601000-00009CrossRefPubMed

Title: Spinal manifestations of Neurofibromatosis type 1
Authors: Ben Shofty
Ori Barzilai
Morsi Khashan
Zvi Lidar
Shlomi Constantini
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Spinal Tumor
Neurofibromatosis Type 1
Published in: Child's Nervous System / Issue 10/2020
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-020-04754-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Spinal manifestations of Neurofibromatosis type 1

Abstract

Background

Purpose

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Purpose

Please log in to get access to this content

Other articles of this Issue 10/2020

James Tait Goodrich, MD, PhD. (4/16/1946–3/30/2020)

Phacomatoses in the pediatric age group

Epilepsy surgery in tuberous sclerosis complex (TSC): emerging techniques and redefinition of treatment goals

Neurofibromatosis type 1–related hydrocephalus: causes and treatment considerations

Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome

Medical treatment of tuberous sclerosis-related epilepsy